The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Factor XII Inhibitors Market Expected To Change Between 2026 And 2030?
The factor xii inhibitors market size has demonstrated significant expansion in recent years. It is anticipated to expand from $1.4 billion in 2025 to $1.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the past can be ascribed to advancements in coagulation biology research, an escalating occurrence of thrombotic disorders, the constraints of conventional anticoagulants, initial positive outcomes in clinical trials for fxii inhibition, and increased investment in rare and specialized therapeutics.
The factor xii inhibitors market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $2.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period is driven by several factors, including the proliferation of late-stage clinical trials, a rising need for safer antithrombotic treatments, the growing adoption of precision medicine, increasing regulatory backing for new anticoagulants, and the extension of fxii inhibitors into inflammatory applications. Key developments expected within this period encompass the accelerated creation of non-bleeding anticoagulant therapies, a heightened emphasis on modulating targeted coagulation pathways, an increase in the clinical assessment of fxii selective inhibitors, the broadening use of rna-based and peptide therapeutics, and the improved application of precision drug design.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp
Which Economic Or Industry Drivers Are Impacting The Factor XII Inhibitors Market?
The increasing occurrence of thrombotic conditions is projected to drive the expansion of the factor XII inhibitors market. These conditions involve the formation of blood clots within veins or arteries, which can obstruct blood flow and lead to severe health issues. The rise in sedentary lifestyles, contributing to inadequate blood circulation and an elevated risk of clot development, is causing an increase in thromboembolic disorders. Factor XII inhibitors address thrombotic disorders by impeding irregular clot formation through the blockade of the contact activation pathway, all while preserving normal hemostasis. This mechanism ensures efficient control of thrombosis while concurrently reducing the likelihood of bleeding. For example, as reported by the US-based government agency, the Centers for Disease Control and Prevention (CDC), in January 2025, approximately 900,000 individuals in the United States suffer from venous thromboembolism, with an estimated 60,000-100,000 Americans succumbing to it each year, and many more facing enduring complications. Consequently, the growing frequency of thrombotic disorders is fueling the expansion of the Factor XII inhibitors market.
How Is The Factor XII Inhibitors Market Structured Across Different Segments?
The factor xii inhibitors market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors
3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies
Which Trends Are Shaping The Future Of The Factor XII Inhibitors Market?
Leading companies operating in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the aim of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics designed to inhibit activated factor XII, preventing abnormal clot formation while preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, secured manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks of hereditary angioedema (HAE). It functions by targeting activated factor XIIa, a key driver in the initiation of HAE attacks, and is administered through a convenient subcutaneous injection pen.
Which Major Players Dominate The Factor XII Inhibitors Market?
Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC
Read the full factor xii inhibitors market report here:
https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report
What Are The Top-Performing Regions Within The Factor XII Inhibitors Market?
North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Factor XII Inhibitors Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30278&type=smp
Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company
Tumor Necrosis Factor Inhibitor Drugs Market Report 2026
Kinase Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
Enzyme Inhibitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model